# Skin probiotics to treat atopic dermatitis

> **NIH NIH R43** · RESVITA BIO, INC. · 2023 · $249,935

## Abstract

Project Summary
 Atopic dermatitis (AD) is a common, chronic inflammatory skin condition characterized
by dry, itchy lesions. Current treatments, including immunomodulators and anti-inflammatory
steroids, can sometimes control symptoms but may also have serious side effects and do not
offer a long-term cure. These treatments may be insufficient because they do not address the
initial role of skin barrier failure in the development of AD, which can lead to a cycle of
inflammation, sensitization, and infection. It is believed that the damage to the skin barrier in AD
is exacerbated or caused by excessive serine protease activity. Proper proteolytic activity is
essential for maintaining the skin barrier and is regulated by proteolysis of the
corneodesmosomes, which is predominantly carried out by kallikrein-related peptidases (KLKs).
KLK5, 7, and 14 are the core proteolytic enzymes in the epidermis and are inhibited by LEKTI
(lympho-epithelial Kazal-type-related inhibitor) fragments.
 Excessive serine protease activity, particularly from KLK5 and KLK7, is thought to be a
primary cause of AD. However, correcting this excess proteolysis in the skin is difficult because
many homeostatic pathways in this organ are controlled by proteases, requiring specific
modulation with minimal antigenicity. Enzyme replacement using LEKTI has not yet been
successful because applied topical peptides are quickly degraded by the many exo- and
endo-proteases present in the skin. Therefore, most KLK inhibitor efforts involve modifying
natural peptide inhibitors to maintain their activity while increasing their lifetime. These small
molecule drug mimics may have significant toxicity concerns due to systemic absorption.
 We propose that the use of genetically engineered topical bacteria for on-site enzyme
replacement could effectively address these challenges. We aim to genetically engineer a
harmless bacterium to temporarily populate the skin microbiome and deliver kallikrein inhibitors
to treat AD. Our platform for continuous production of peptide drugs on the skin surface has the
potential to revolutionize the treatment of atopic dermatitis.
 In this Phase I SBIR, we will establish the safety of our topical application and
demonstrate bioactive secretion of our target inhibitors. This will provide a strong foundation to
transition to Phase 2 where we will establish safety and efficacy in murine genetic models.

## Key facts

- **NIH application ID:** 10760367
- **Project number:** 1R43AI179327-01
- **Recipient organization:** RESVITA BIO, INC.
- **Principal Investigator:** Amin Zargar
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $249,935
- **Award type:** 1
- **Project period:** 2023-07-01 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10760367

## Citation

> US National Institutes of Health, RePORTER application 10760367, Skin probiotics to treat atopic dermatitis (1R43AI179327-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10760367. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*